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sions included no evidence of a diabetes diagnosis prior to study intervals or death 
prior to the end of intervals. Indicated services based on ADA guidelines for lipid (LI) 
, retina examinations (RE), microalbuminuria (MA), serum creatinine (SC), inﬂuenza 
vaccinations (FV), and A1c tests were identiﬁed from CPT codes and HCPCS codes 
(≥ 2 annually for A1c tests and ≥1 annually for other tests). Logistic regression assessed 
associations between subprogram and assessments controlling for age, gender, ethnic-
ity, comorbidity, and state region. RESULTS: A sample of 22,017 persons, with 57% 
FFS, 26% CM and 17% MC was identiﬁed. Overall, proportions (95% C.I.) meeting 
recommendations were 63.5%, (62.9 – 64.1) SC, 37.2% (36.5 – 37.8) LI, 30.5% (29.9 
– 31.1) RE, 23.3% (22.8 – 23.9) MA, 18.2% (17.6 – 18.7) FV, and 15.6% (15.1 – 
16.1) A1c tests. Compared to FFS, odds ratios ranged from 1.38 for RE to 4.74 for 
LI under CM and excluding RE which did not differ, 1.39 for FV to 3.78 for LI under 
MC (P ≤ 0.001 for all). CONCLUSIONS: While A1c rates are likely low due to low 
claims submission for point of service A1c tests, other rates are likely representative. 
Associations between subprograms and assessments may indicate strategies such as 
chronic disease management and primary care coordination may be effective in 
increasing diabetes care assessments.
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OBJECTIVES: To examine the effect of an employer sponsored, community phar-
macy based medication therapy management program (MTM) on clinical outcomes 
in patients with diabetes. METHODS: A one year prospective, pre-post longitudinal 
study. Study Participants were employees and dependents of the City of Toledo in 
Ohio who received care at local independent pharmacies and were seen every three 
months. Enrolled participants had diabetes and/or other comorbid conditions. Data 
collected: clinical (A1c, blood pressure, BMI), social (caffeine and alcohol intake, 
exercise and smoking habits, etc.), process measures (podiatrist, ophthalmologist, 
and dentist visits). Data was analyzed using SPSS v. 16.0. Descriptive statistics and 
Friedman tests were used. Data was analyzed for baseline, 6 months, and 12 months. 
RESULTS: One hundred and one patients enrolled at baseline. Mean A1c improved 
from 7.77 to 7.5 (p = 0.866). Patients with uncontrolled A1c at baseline improved 
from a mean of 8.87 to 8.18 (p = 0.247) at baseline and 12 months. Systolic blood 
pressure improved from 136.17 mmHg to 130.57 mmHg (p = 0.189) and signiﬁ-
cantly improved for patients with baseline SBP ≥ 140 mmHg (p < 0.001). Diastolic 
blood pressure improved from 84.4 mmHg to 80.2 mmHg (p = 0.252) and signiﬁ-
cantly improved for patients with baseline DBP ≥ 90 mmHg (p < 0.001). Social 
measures showed a 34.15% decrease in caffeine intake and 44.12% increase in 
exercise habits. There was a 35.90% increase in podiatrist visits, a 13.51% increase 
in dental visits, and a 29.73% increase in ophthalmologist visits. Use of sick days 
decreased from 1.12 ± 5.32 days per 3 months to 0.09 ± 0.39 (p = 0.368). CON-
CLUSIONS: This community pharmacy MTM program has shown improved out-
comes for patients who participated in pharmacist-guided interventions over a one 
year time period.
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OBJECTIVES: Opioids have commonly been used to treat chronic pain conditions, 
including diabetic peripheral neuropathic pain (DPNP), but tolerance issues have 
limited their use by providers. Newer classes of drugs are now approved for DPNP 
therapy, but no published data currently exists that assess changes in the utilization 
of opioid therapy following treatment with these newer agents. This study compared 
the use of opioids between DPNP patients who initiated treatment with duloxetine 
versus other standard of care (SOC) DPNP treatments. METHODS: This retrospective 
cohort study assessed commercially-insured DPNP patients aged 18 to 64 over a 1-year 
follow-up period who initiated treatment with either duloxetine or other SOC treat-
ments (tricyclic, venlafaxine, gabapentin, pregabalin) between March 1,2005 and 
December 31, 2005. Initiation was deﬁned as a 90-day period without available study 
medication. Dispense date of the ﬁrst study medication initiation was denoted as the 
index date. Selected patients had 12 months continuous enrollment before and after 
the index date, and no opioid pill coverage during the 90 days prior to initiation. 
Patients were matched to duloxetine-treated patients via propensity scoring, control-
ling for demographics, comorbidities, prior health care utilization and costs, and 
medication history. RESULTS: The matched sample included 117 patients in each of 
the duloxetine and SOC cohorts. Compared with SOC patients, duloxetine-treated 
patients were less likely to use any opioids (52.1% vs. 84.6%, p < 0.05) over the 
12-month post-index period. Duloxetine-treated patients, on average, had 2 fewer 
opioid prescriptions dispensed, 27 fewer days on opioids, 120 days greater delay in 
subsequent opioid use, and 1816mg lower morphine equivalent dosage than SOC 
patients (all p < 0.05). Also, duloxetine-treated patients had signiﬁcantly lower total 
($18,623 vs. $30,602, p < 0.05) and outpatient costs ($7,371 vs. $15,343, p < 0.05). 
CONCLUSIONS: Duloxetine treatment is associated with deferred and reduced 
opioid use among DPNP patients. Patients initiated on duloxetine also had lower 
health care costs.
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OBJECTIVES: The objective of this study was to evaluate whether Medicaid coverage 
gap is associated with higher risks for diabetes-speciﬁc hospitalizations and all-cause 
mortality among working-aged adults (i.e., those aged 19–64 years) with diabetes. 
METHODS: Using administrative claims data, we conducted a retrospective cohort 
study of working-aged adults with diabetes and who were enrolled in a state Medicaid 
program. Coverage gap was deﬁned as at least one month interruption in their Med-
icaid enrollment from January 2002 to December 2003. The primary outcomes of 
interest were diabetes-speciﬁc hospitalization and all-cause mortality during follow-up 
(January to December 2004). Multivariate regression analyses were performed to 
assess the independent association between adherence to statin and outcome measures. 
Key confounding variables include age, gender, race, comorbidities (measured using 
Charlson Comorbidity Index), prior hospitalization due to diabetes, and use of medi-
cations essential to diabetes management including oral hypoglycemic agents, insulin, 
antihypertensive agents, and statins. RESULTS: A total 24,996 patients were included 
in the study. Mean age 50.2 ± 10.3 years, 29.7% male, 70.3 female; 30.3% white, 
59.3% black. About 86% had continuous Medicaid coverage and 14% had at least 
one month gap in their Medicaid coverage. During follow-up, those with at least 
one-month in their coverage were 16.2% less likely (OR: 0.838; 95%CI: 0.714–0.985) 
to have diabetes-speciﬁc hospital admissions and 44.9% less likely (OR: 0.551; 
95%CI: 0.430–0.706) to have all-cause mortality during the follow up period. CON-
CLUSIONS: The results from this study suggest that gaps in Medicaid coverage are 
not associated with higher risks for diabetes-speciﬁc hospitalizations and all-cause 
mortality in the follow up period. However, the study lacked information on why 
coverage gaps occurred and whether individuals with coverage gaps transitioned to 
other insurance coverage.
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OBJECTIVES: To examine racial and ethnic disparities in quality of health care 
(receipt of diabetes services, timeliness, and patient centeredness) among adults with 
diabetes in the U.S. in the years of 2005 and 2006. METHODS: The 2005 and 
2006 Medical Expenditure Panel Survey (MEPS) full-year consolidated data ﬁles 
including the Diabetes Care Survey and the Self-Administered Questionnaire were 
combined and analyzed. The racial and ethnic disparities in receipt of recommended 
diabetes services (A1C test, foot exam, eye exam, lipid proﬁle, and inﬂuenza immu-
nization), timeliness, and patient centeredness were examined. Chi-square test and 
logistic regression were conducted to evaluate the disparities before and after control-
ling for the confounding factors (age, gender, family income, education, health insur-
ance coverage, residential location, and language spoken most often at home). 
RESULTS: In 2005–2006, the racial and ethnic disparities in quality of health care 
among U.S. adults with diabetes still exist even after controlling for demographic 
and socioeconomic factors. African Americans and Hispanics were less likely to 
receive recommended diabetes services and patient-centered health care than Whites. 
African Americans had more foot examinations than Whites and Hispanics. There 
was no signiﬁcant difference in timeliness of health care among racial and ethnic 
groups. CONCLUSIONS: Racial and ethnic disparities in receipt of recommended 
diabetes services and patient centeredness of health care among adults with diabetes 
remained in the U.S. in 2005–2006. Age, family income, health insurance coverage, 
education, residential location, and English-speaking were correlated with racial and 
ethnic disparities. As this study is focused on disparities among only Whites, African 
Americans, and Hispanics, future studies comparing possible differences among other 
U.S. ethnic groups (e.g., American Indians or Alaska Natives) are needed using 
more-year, larger databases.
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OBJECTIVES: The objective of this study was to evaluate the main effect of health 
insurance plan type on health resource utilization (emergency room (ER) visit or 
hospital admission) in privately insured patients with Type 2 diabetes between the 
ages of 18 to 64 years. The outcomes of interest were the odds of an emergency room 
visit or a hospital admission associated in patients with Type 2 diabetes. METHODS: 
The data source was the 2000–2001 MarketScan database, which is comprised of 
administrative claims data for over 2.5 million privately insured individuals in the 
United States. The odds of an emergency room visit or hospital admission were evalu-
ated using multiple logistic regression models speciﬁed to control for demographic and 
clinical characteristics of the target patient population. A propensity score analysis 
using the stratiﬁcation approach was also done to further control for selection bias. 
RESULTS: After adjusting for the covariates, patients enrolled in FFS plans were 
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signiﬁcantly more likely to experience an ER visit or an inpatient stay compared to 
patients in capitated plans (odds ratio for ER visit: 1.64, p < 0.05; odds ratio for an 
inpatient stay: 1.11, p < 0.05). CONCLUSIONS: The results of this study conﬁrm 
that utilization rates are higher in FFS plans; however, the strength of the association 
was not as robust when the regression models were adjusted for propensity score. 
Capitated plans seek to reduce resource utilization.
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OBJECTIVES: This paper compares physician’s cost awareness of types of payments 
and insurance status at the point of visit, using two analytical datasets extracted from 
the National Ambulatory Medical Care survey (NAMCS) on patients diagnosed with 
Type II diabetes without complications. It analyzes the effects of various changes in 
the physician survey. METHODS: Two analytical datasets are constructed for diabetic 
patients Type II with no complication identiﬁed with code 25.00, one of 694 individu-
als in 1996 and one of 620 for 2005. Pharmacological treatment has been deﬁned by 
building two drug lists for 1995/1996/1997 and 2004–2005–2006 from Facts and 
Comparisons books (one year before - one year after the year of reference) and the 
Brixner et als study (2008). Drug codes used for the two periods are generic codes. 
The coding has been revised in order to integrate the withdrawal of FDA codes and 
the transition to new Multum drug classiﬁcation system. A disease economic model 
is used. Dependent variables represent access and use of drug therapy. RESULTS: 
Drug codes for the two references periods substantially differ. New development of 
the disease model are described between 1996 and 2005 to integrate these drug codes 
changes,the introduction of electronic records, new types of ﬁnancial information, new 
beneﬁt designs and changes of clinical guidelines. It transforms the previous series of 
cross sectional modeling tested on 3 chronic conditions into a time series and dynamic 
framework. The model describes prescribing patterns of new versus old classes (espe-
cially TZD and new insulin analogs), evolution of modes of administration and impact 
of electronic records. CONCLUSIONS: The paper contributes to show the interest of 
disease modeling not only by medical schools but also with an economic perspective. 
Even after triages from health care administrators for categorization of patients into 
various health plans, physicians are cost aware at the time of visit and this inﬂuences 
their prescribing decisions.
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OBJECTIVES: Prevention or mediation of adverse events can signiﬁcantly impact a 
patient’s quality of life and their employer’s health care costs. Decision modeling can 
be utilized to map pharmacists interventions provided through an employee-sponsored 
medication therapy management (MTM) program and calculate consequent cost 
savings associated with improved clinical outcomes. METHODS: A total of 700 
employees from 2 employer groups participate in a pharmacist provided MTM 
program. A team of clinicians and researchers classiﬁed and created codes for speciﬁc 
pharmacist interventions, resultant physician and/or patient responses, and consequent 
outcomes. Data was extracted from patient charts and entered into Microsoft Excel. 
Costs associated with each decision outcome were calculated from claims data. A 
one-year decision-analytic model was constructed using TreeAge Pro Suite 2008 to 
identify the cost savings per intervention. RESULTS: A total of 218 interventions were 
made by the pharmacists. The most frequently used interventions were “explained and 
advised the use of pattern management” (N = 95, 43.4%) and “alerted the physician 
of an abnormal A1c level” (N = 64, 29.2%). Cost savings resulting from diabetic 
interventions for ER visits ($71.00 – $337 PPPY), inpatient hospitalization ($460.00 
– $2360.00 PPPY), and total costs ($26.00 – $274.00 PPPY). All but one intervention 
resulted in a loss of cost savings for ofﬁce visits, indicating that patients visited spe-
cialty physicians more often after beginning the program. The total cost savings for 
these interventions were $165.00 PPPY and $145.00 PPPY, respectively. CONCLU-
SIONS: This decision-analytic model can be used as a rubric for providers seeking the 
most effective interventions to utilize for MTM programs, thereby reducing trial-and-
error and diminishing health care costs. The model illustrates the potential return on 
investment the employer realized as a result of sponsoring employee participation in 
this program.
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OBJECTIVES: Literature suggests that while pharmacists may be viewed as the most 
trusted health care professionals by patients, other health care professionals may 
often fail to trust them with making decisions regarding drug therapy regimens. 
Limited information is available regarding physicians’ therapy decisions based on 
pharmacist’s recommendations and the resulting patient clinical outcomes. This study 
aimed at ﬁnding if physicians’ therapy decisions based on pharmacist’s recommenda-
tions lead to optimal patient outcomes. METHODS: Approximately 700 employees 
from 2 employer groups have participated in an employer-supported pharmacist 
provided disease state management program. The program is provided at seven 
independent pharmacies across Northwest Ohio. A team of clinical pharmacists and 
researchers classiﬁed and created codes for speciﬁc pharmacist-provided interventions, 
resultant physician and/or patient responses, and consequent outcomes. Data was 
extracted from patient charts and entered into Microsoft Excel. Frequencies and 
percentages of pharmacists’ interventions, physicians’ responses and outcomes were 
calculated using SPSS ver. 17.0. A decision tree was created using TreeAge Pro Suite 
2008 to map interventions to responses to improved/unimproved outcomes. 
RESULTS: A total of 446 pharmacist interventions with corresponding physician 
responses and patient outcomes were made. The most frequent interventions involved 
drug therapy (N = 138, 31%) and formulary management (N = 105, 23.5%). The 
most frequent responses by physicians were “physician acknowledged recommenda-
tion, monitoring added” (N = 58, 13%) and “physician added a medication” (N = 
51, 11.4%). Physicians responded favorably to the pharmacists’ interventions 54.1% 
of the time. When physicians responded favorably, an improvement was seen in 
91.2% of patient outcomes compared to only 64% when physicians declined or did 
not respond to pharmacists’ interventions. CONCLUSIONS: Positive health out-
comes result from therapy decisions made by physicians following pharmacists’ 
recommendations. In an effort to save costs and improve care, pharmacist-physician 
collaboration is essential.
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OBJECTIVES: To evaluate selected Healthcare Effectiveness Data and Information 
Set (HEDIS) comprehensive diabetes care measures in the i3 Innovus database by using 
the Retrospective Analysis for Diabetes Action and Reporting (RADAR) tool. 
METHODS: i3 Innovus data assets including medical and pharmacy claims from May 
2006 to May 2008 were used in the RADAR tool to assess the yearly rate of glyco-
sylated hemoglobin (HbA1c) testing and low-density lipoprotein-cholesterol (LDL-C) 
screening. Other HEDIS comprehensive diabetes care–related measures reported by 
the RADAR tool included the rate of patients with (a) hypertension; (b) nephropathy; 
and (c) retinopathy. Variables such as demographic, clinical, pharmacy, and medical 
utilization patterns along with medication adherence were also reported. RESULTS: 
A total of 287,195 patients with diabetes were identiﬁed, with 92% of the patients 
identiﬁed as having type 2 diabetes. Mean age of the patients was 53 years, and 52% 
were male. Over 70% of the patients with diabetes had cardiovascular risk factors 
such as hypertension; 4%, 13%, and 11% of the diabetes population had nephropa-
thy, neuropathy, and retinopathy, respectively. Sixty-seven percent of the diabetes 
patients received HbA1c testing, while 71% of the patients received LDL-C screening 
within one year. Testing within one year was less than the national HEDIS Medicaid 
25th percentile level (74.4%) for HbA1c and greater for LDL-C screening (66.9%). 
The RADAR tool effectively evaluated the selected HEDIS comprehensive diabetes 
care measures in the i3 Innovus database. CONCLUSIONS: In this population, LDL-C 
screenings within one year for diabetes patients were above the national HEDIS low-
performance level, while HbA1c testing within one year for diabetes patients was 
below the low-performance level, utilizing the RADAR tool for analyses. These ﬁnd-
ings indicate an opportunity for improvement.
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OBJECTIVES: Type 2 diabetes mellitus is serious condition associated of chronic 
complications whose economic impact on both patients and society is constantly 
increasing. Diabetics are the 4st in the drug spending in Slovakia. Our objectives was 
to explore drug costs for diabetes and besides the costs to explore also drug consump-
tion and number treated patients with antidiabetics. METHODS: The data on drugs 
consumption were from national databases IMS Health and Pharmadata Ltd. with 
293.935 diabetic patients cohort data in 4 years. To look into the impact of the drug 
policies in the Slovak Republic in 2006–2009. We calculated the impact of several 
regulatory measures on the size of the market and health insurance expenditure. 
Among the evaluated measures were: a) Lowering the VAT for drugs from 19% to 
10%, effective from 2007 b) ﬂat price cut in 2007 (-6.6%) and in 2008 (-7.4%) c) 
introduction of degressive mark-up for wholesalers and for pharmacies d) ﬁrst and 
second rounds of the international reference pricing for all drugs in 2009. RESULTS: 
The total antidiabetics volume (oral antidiabetics + insulin) of the Slovak market in 
2009 was °38.9 mil in manufacturers´ prices. 5% of the population with type 2 dia-
betes accounted for 8% of the total health care expenditure in Slovakia. In 2006 to 
2009 number of treated patients with antidiabetics increased by 11%. In 2006 to 2009 
7 new antidiabetics (molecules) entered the market. The regression results (40.0 vs 
°38.9 mil) suggested a positive relationship between the reimbursement price and 
